Abstract:Understanding the mechanisms that give rise to neurodegenerative diseases, in particular Alzheimer's disease, is of fundamental importance for the development of mechanism-based therapies. Alzheimer's disease is defined by the development of extracellular deposits of beta-amyloid and intraneuronal tau inclusions. Of these, tau inclusions correlate better with the loss of cognitive function. Moreover, tau inclusions are also found in a large number of other neurodegenerative diseases, including progressive supranuclear palsy, chronic traumatic encephalopathy and Pick's disease. Of the protein assemblies characteristic of human neurodegenerative diseases, those made of tau are the most common. Tau aggregates appear to spread through the brain via interconnected nerve cells, giving rise to the concept that they do so through prion-like mechanisms. In experimental systems, such as tauopathy mouse models, the spreading of tau pathology can be recapitulated following the injection of sonicated tau seeds. However, at present it is not possible to validate the prion-like spreading hypothesis from these experiments and extrapolate to the human brain. In order to address this fundamental question, we have quantified tau amplification at the molecular level by studying the evolution of single tau aggregates in vitro over extended times and fitted this data to obtain the rate constants for fibril elongation and fragmentation . We have then developed a simple model to estimate the rate of spreading through an animal or human brain based on these rate constants. We show that the spreading efficiency of tau aggregates depends on their elongation and fragmentation rates, as well as the availability of free cytosolic tau. Importantly, our spreading model is able to recapitulate spreading times in vivo and provides, for the first time, a quantitative framework for analysing the results from animal experiments and for linking them to the development of neuropathological changes in human brain. The prion-like propagation of tau occurs by elongation and fragmentation allowing a simple model to predict the spreading rate of tau assemblies in both animal models and humans. This model shows that inhibiting the rate of tau propagation would be an effective therapeutic strategy.

Spreading of pathology in neurodegenerative diseases: a focus on human studies

Neuron-to-Neuron Transmission of Neurodegenerative Pathology

Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases

Spreading of neurodegenerative pathology via neuron-to-neuron transmission of β-amyloid

Interactions of pathological proteins in neurodegenerative diseases

Targeting Prion-Like Protein Spreading in Neurodegenerative Diseases

Disease and brain region specific immune response profiles in neurodegenerative diseases with pure and mixed protein pathologies

Cell-to-cell Transmission of Pathogenic Proteins in Neurodegenerative Diseases

A review of proposed mechanisms for neurodegenerative disease

Neuropathological Staging of Brain Pathology in Sporadic Parkinson's disease: Separating the Wheat from the Chaff

Protein transmission in neurodegenerative disease

Early Diagnosis of Neurodegenerative Diseases: What Has Been Undertaken to Promote the Transition from PET to Fluorescence Tracers

Molecular mechanisms of proteinopathies across neurodegenerative disease: a review

The Search for a Universal Treatment for Defined and Mixed Pathology Neurodegenerative Diseases

[Neuropathology of the Neurodegenerative Diseases]

Prionoid Proteins in the Pathogenesis of Neurodegenerative Diseases

Pathology of neurodegenerative disease for the general neurologist

Brain Regions Susceptible to Alpha-Synuclein Spreading

Protein misfolding and aggregation in neurodegenerative diseases: a review of pathogeneses, novel detection strategies, and potential therapeutics

Deciphering the prion-like behavior of pathogenic protein aggregates in neurodegenerative diseases

O3‐01‐05: in vitro measurements of tau aggregate elongation and fragmentation rates allow the modelling of prion‐like spreading in humans